PubMed Health⌕ Search

Biomedical subjects

W A Ritschel

Publications and source records attributed to W A Ritschel.

At least 19 recordsLinked to original sources
PubMed1992

Prediction of the volume of distribution of 7-hydroxycoumarin in man from in vitro and ex vivo data obtained in rat.

The essential parameter to estimate the first dose size of a drug in man is the volume of distribution. For a drug that has never been used in man before, estimates of the volume of distribution can only be obtained from animals and in vitro data. The purpose of this study was to compare various approaches presented in the literature for predicting the volume of distribution at steady state (VSS) and the terminal phase volume of distribution (Vd beta) in man. A lipophilic active metabolite of coumarin, 7-hydroxycoumarin (7OHC), was selected for this investigation. This compound is extensively metabolized in both the central and peripheral compartments. Of the six methods evaluated, only an empirical allometric approach yielded a reasonable estimate of VSS. All methods underestimated VSS and none of the applicable methods were able to predict Vd beta. The reason for this discrepancy may be due to the fact that the calculation of VSS in man was done assuming elimination from the central compartment.

Animals↗
PubMed1992

The allometric approach for interspecies scaling of pharmacokinetic parameters.

A long standing problem in pharmacokinetics and toxicology is the extrapolation and correlation between results obtained in different animal species and man. Animal data may be scaled-up to predict PPs in man using the allometric approach. The allometric approach is empirical, but easy, and is based on the fact that the underlying physiological processes such as blood flow, heartbeat duration, breath duration etc. are essentially physical and related to B. This approach is generally applicable to compounds that are essentially renally excreted. For substances that are highly extracted by the liver, Cltot is a function of the LBF among various species. Based on the concept of neoteny, use of brain weight affords a more correct approach to the scaling of Cl(int) of low extraction ratio drugs. By using the invariant pharmacokinetic time, the superficial differences in concentration-time profiles due to chronological time among different species are removed. Finally, as Boxenbaum (1984) has said "parameters to be scaled, independent variables, and the mathematical relationships used in the scaling process are all at the discretion of the investigator. There are no proper or improper approaches; the only limitations are those imposed by the investigator."

Animals↗
PubMed1992

Development of a colonic release capsule dosage form and the absorption of insulin.

Since the colon is relatively low in peptidase activity and drainage into the lymphatics is maximized, a peroral dosage form was developed to deliver insulin to the colon. Microemulsions, used as a vehicle for insulin, were gelled using Cab-O-Sil, and filled into gelatin capsules pretreated with formaldehyde vapor. The capsules were coated with Eudragit NE 30 D, Eudragit S100 and cellulose acetate phthalate polymers of pH-dependent and time-controlled release mechanisms. In vitro dissolution profiles of the capsule coating, using sodium salicylate as the marker, show that dissolution of the capsule begins at 4 h, at pH 5.5, and is completed at 8 h, at pH 7.7, simulating the gastrointestinal transit and pH profile of the dog. An in vivo crossover study in beagle dogs was carried out employing the following treatments: i.v. insulin, p.o. insulin microemulsion and colonic release capsule dosage form without insulin (CRC), were used as controls, a colonic release capsule dosage form with insulin (CRI) and additionally with sodium laurylsulfate (CRIL) or aprotinin (CRIA) as sorption promoter and enzyme inhibitor, respectively. Evaluation was done by measuring the reduction in blood glucose concentration levels. The pharmacological availability (P.A.) is the ratio of the area under the baseline curve (AUC), expressed as percent glucose reduction from baseline vs time, of the p.o. dosage forms to i.v. insulin administration, corrected for body weight and dose size. The P.A. for the p.o. microemulsion, CRC, CRI, CRIL and CRIA were 2.1, 0.4, 5.0, 2.7 and 6.2%, respectively. Insulin release occurred throughout the GI tract, with the exception of the stomach. Tmax occurred at 6.4 h for CRIA; the majority of insulin is taken up after the colonic arrival time is reached in the dog (4-6 h). Duration of the reduction in blood glucose levels occurred for 14 h with the CRIA dosage form.

Animals↗
PubMed1992

Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs.

Bioavailability and pharmacokinetics of papaverine HCl was studied in beagle dogs following intravenous injection, intracorporeal injection and topically applied gel on the penis. Also the effect of the sorption promoter Labrafil M-1944 CS on the permeation of papaverine from two gel formulations (PT and PTL) containing the co-solvent Transcutol was evaluated. Blood samples were analyzed by high performance liquid chromatography (HPLC). The pharmacokinetic parameters were determined using either curve-fitting (RE-SID) or compartment model independent method (AUC-RPP). The plasma concentration-time profiles show that papaverine HCl pharmacokinetics is best described by an open two-compartment model. The absolute bioavailability of papaverine HCl was determined to be 102.4%, 9.1%, and 12.4%, respectively, following intracorporeal injection, gel PT and gel PTL administration.

Administration, Topical↗
PubMed1991

Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs.

This in vivo study was designed to obtain bioavailability data and a definite pharmacokinetic profile of papaverine HCl in Beagle dogs following intravenous (IV), peroral (PO), rectal, vaginal, topical, and buccal administration of different papaverine HCl formulations. Blood samples were analyzed by high-performance liquid chromatography. The pharmacokinetic parameters were determined using either a curve fitting program (RESID) or a compartment model independent program (AUC-RPP). The plasma concentration-time profiles show that papaverine HCl pharmacokinetics is best described by an open two-compartment model. The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.

Administration, Buccal↗
PubMed1991

Development and evaluation of an intracutaneous depot formulation of corticosteroids using Transcutol as a cosolvent: in-vitro, ex-vivo and in-vivo rat studies.

A topical delivery system has been developed using 50% Transcutol (diethylene glycol monoethyl ether) to decrease the body burden of topically administered dexamethasone and hydrocortisone. The delivery system was evaluated in-vitro using a dissolution apparatus to measure the release of steroid from the gel. In 10 h, 29.6 +/- 0.39% dexamethasone and 45.5 +/- 0.84% hydrocortisone was released from the formulation compared with 23.0 +/- 0.48 and 39.9 +/- 0.77%, respectively, from control formulations without Transcutol. Ex-vivo evaluation was made using rat whole skin in a diffusion cell; the amount of steroid reaching the acceptor cell was significantly less from the formulation containing Transcutol compared with controls. There was also a 2-fold increase in the retention of dexamethasone and a 3-fold increase in the retention of hydrocortisone in the skin at the end of the permeation experiments compared with control experiments. In-vivo studies were made using a formulation containing [3H]hydrocortisone applied to rat skin, followed by measurement of total radioactivity in the blood. For the Transcutol formulation the area under the blood concentration-time curve (0-96 h) was 6.06 +/- 1.27 compared with 2.52 +/- 0.43 x 10(6) d min-1 mL-1 h for the control formulation, indicating a 58% reduction in body burden.

Administration, Topical↗
PubMed1991

Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species.

The pharmacokinetic parameters, total body clearance, apparent volume of distribution and the terminal elimination half-life of coumarin were correlated among six mammalian species. It was demonstrated that the total body clearance was highly related to the liver blood flow, liver weight and body weight. The apparent volume of distribution appeared to be related only to body weight. The elimination half-life, which is dependent upon both the apparent volume of distribution and total body clearance, was poorly correlated with all physiologic variables that were evaluated. Hence, it appears that only the primary pharmacokinetic parameters of coumarin display a definite interspecies relationship.

Animals↗
PubMed1991

In vivo-in vitro correlation of salbutamol release from a controlled release osmotic pump delivery system.

The drug release of salbutamol from a controlled release (osmotic pump) tablet was determined in vitro by four different dissolution apparatuses. From published in vivo data, percent of drug absorbed and percent of drug released in vivo were estimated. The highest correlation was obtained between percentage released in vitro versus percentage released in vivo using polynomial regression.

Administration, Oral↗
PubMed1991

Biopharmaceutic evaluation of furosemide as a potential candidate for a modified release peroral dosage form.

An attempt was made to evaluate some of the criteria for developing a modified release peroral dosage form for furosemide which has a poor bioavailability when given in the conventional peroral dosage forms. The pathway of absorption for furosemide was studied ex vivo employing the Wilson-Wiseman test. Passive absorption was found to be the predominant mechanism of transport across the ileum of the guinea pig followed by active transport to the extent of about 17%. The in situ procedure to study the extent of absorption of furosemide from the various sites in the lumen of the gastrointestinal tract of the rat indicated the stomach to be the major site of absorption followed by the duodenum. It is hence postulated that due to the site-specificity and mechanism of absorption a peroral modified release dosage form having a longer gastric residence time could possibly increase the bioavailability of furosemide.

Administration, Oral↗
PubMed1991

Comparison of continuous, constant rate enteral tube feeding in supine patients to bolus food intake in ambulatory, healthy subjects regarding bioavailability of perorally administered cefroxadine.

Stabilized, bedridden, inactive trauma patients on enteral nutrition via continuous, constant rate tube feeding (2 different formulas) were given a single dose of cefroxadine p.o. There were no differences in the pharmacokinetic parameters between the groups on different enteral nutrition. These patients were compared to cefroxadine absorption in ambulatory healthy subjects after a standardized meal (bolus-fed). The mean residence time was significantly longer in the patients, and the extent of absorption was slightly reduced with one enteral nutrition formulation and significantly reduced with the other. The other pharmacokinetic parameters were not significantly different. The difference is believed to be caused by reduction in splanchnic blood flow in the immobilized patients, weakening of migrating motor complex due to tube feeding and the lower temperature (4 degrees C) of enteral nutrition.

Administration, Oral↗
PubMed1991

Development of an intracutaneous depot for drugs. Binding, drug accumulation and retention studies, and mechanism of depot.

In previous studies we reported that the permeation of dexamethasone and hydrocortisone across the skin was decreased and penetration into the skin was increased in the presence of Transcutol (TC) when compared to water as a solvent. The objective of this investigation was to study the effect of TC on the binding of dexamethasone and hydrocortisone to the skin, and on the accumulation and retention in the skin. Adsorption and desorption studies were conducted for dexamethasone and hydrocortisone with full thickness skin (FTS), and epidermis. The amount of dexamethasone and hydrocortisone adsorbed and desorbed with FTS and epidermis was essentially the same. In the presence of TC the amount of dexamethasone and hydrocortisone adsorbed was increased by 100% with both FTS and epidermis, whereas there was no difference in the amount of dexamethasone and hydrocortisone desorbed. A topical delivery system was developed with and without TC and was evaluated in vivo using the rat as an animal model for hydrocortisone accumulation after multiple dosing. The systemic body burden was reduced by 70% and skin retention of hydrocortisone was increased by 100% in all the layers of the skin. The detection of hydrocortisone accumulation and retention were studied by autoradiography and electron microscopy, and the results support the hydrocortisone depot in the skin due to TC.

Administration, Cutaneous↗
PubMed1991

An approach to select the appropriate statistical method for testing bioequivalence.

Since most bioavailability studies are usually done with only a limited number of volunteers (usually 10-30), the statistical properties of the calculated bioavailability parameters are not well defined. The established statistical methods to test bioequivalence are usually based on either the assumption of normality or a symmetrical distribution. However, the decision of which method to apply, depends primarily on the distributional assumption of the data. In this study, an approach is followed where the small data base of a limited number of volunteers is expanded by adding pseudo-volunteers by "bootstrap" simulations. From such a larger data base it is easier to determine the statistical distributional properties of bioavailability parameters, which in its turn leads to the identification of an appropriate statistical method. With more certainty on which statistical method to apply, the original data can be used more effectively in testing for bioequivalence. In this paper, comparisons are made between the distributions of bioavailability parameters of an actual 60-volunteer study and those of two simulated data sets. Each such data set contained a random sample of 10 volunteers each (from the 60 volunteers), together with 50 pseudo-volunteers. These 50 volunteers were simulated from the random sample of 10 real volunteers. Good correspondences were obtained when comparing these two data sets with the original data, which indicated the validity to use this approach in bioavailability studies where a small number of volunteers had been used. This method proved useful to define the distributional properties for a relative small number of parameter-values available.

Biological Availability↗
PubMed1991

In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs.

The purpose of this study was to compare experimental formulations containing hydrochlorothiazide (CAS 58-93-5)/triamterene (HCT/TRI) in vitro and in vivo to a commercial tablet formulation (standard). The beagle dog was verified as a good model and was used for the in vivo studies. The commercial tablet and the experimental fast release formulation (FR) resulted in 100% release of HCT within 30 min in dissolution tests, whereas, the slow release formulation (SR) released only 54% HCT after 4 h. Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet. The experimental results indicate that HCT absorption occurs throughout the small intestine.

Animals↗
PubMed1991

Targeting in the gastrointestinal tract: new approaches.

Most drug products are administered via the alimentary canal; prominent are the dosage forms which are swallowed, i.e., p.o. dosage forms, followed by those administered within the oral and the rectal cavities. The innermost surface of the alimentary canal is the epithelial lining which is void of keratinized superficial layers. The epithelium at both ends of the canal, i.e., oral cavity and esophagus, and anal canal is a multilayered (20-50 layers) stratified squamous epithelium, whereas that of the rest of the canal, i.e., gaster, small and large intestine and rectum is a single layer of columnar cells. The drainage is via both venous blood capillaries and lymphatic vessels. Blood drainage from the oral cavity and the lower end of the rectum is directly into systemic circulation via the vena cava. From the GI tract, however, the blood quantitatively passes through the portal vein and liver, hence is available for first-pass effect prior to entering systemic circulation. Targeting can be approached from two angles: 1) to exert the pharmacologic response at a specific site, or 2) to utilize a specific site for drug absorption. Targeting utilizes the anatomic, histologic, physiologic and biochemical features of various segments within the alimentary canal, paired with the design of special drug delivery systems or devices, and the use of special vehicle substances, such as polymers, bioadhesives, sorption promoters, or chemical modification (pro-drug) of the active moiety. Numerous examples of new types of drug delivery systems are presented. Many novel drug delivery systems discussed are still in experimental stage and evaluation, or even in the conceptual stage. However, it is anticipated that they all will contribute to further advancement in optimizing drug therapy.

Animals↗